(Q37702739)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Eileen M Broomall

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sonya M Reynolds

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

published in

Postgraduate Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

121-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20203463%20AND%20SRC:MED&resulttype=core&format=json

Marketing HPV vaccine: implications for adolescent health and medical professionalism

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Prevalence of HPV infection among females in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Determinants of genital human papillomavirus infection in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Chapter 16: HPV vaccines in immunocompromised women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Human papillomavirus (HPV) in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Anaphylaxis following quadrivalent human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Health and economic implications of HPV vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129

Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2129